ABCL-316 Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2)
Spira, A. Zhou, X. Liao, L. Yu, E. Chen, L. Lau, A. Wang, Y. Gnanasakthy, A. Radford, John A Hamadani, M.
Spira, A.
Zhou, X.
Liao, L.
Yu, E.
Chen, L.
Lau, A.
Wang, Y.
Gnanasakthy, A.
Radford, John A
Hamadani, M.
Citations
Altmetric:
Abstract
Context: Skin toxicity was commonly reported among patients
treated with loncastuximab tesirine (loncastuximab tesirine-lpyl;
Lonca). Most skin toxicities (~90%) were grade 1 or 2, but their
impact on health-related quality of life (HRQOL) was unknown.
Objective: This post hoc analysis assesses whether skin toxicity is
associated with HRQOL and patient tolerability to Lonca. Design:
The LOTIS-2 study (NCT03589469) is a single-arm, open label, phase 2 study of 145 adult patients with relapsed/refractory
diffuse large B-cell lymphoma after 2 prior treatments. Patients
received Lonca as an intravenous infusion on day 1 of each 3-week
treatment cycle for up to 1 year. EQ-5D and FACT-Lym scores
were collected. Mean changes from baseline were summarized by
visit and with/without skin toxicity. The least-squares means of the
differences were estimated using the analysis of covariance models to
adjust for age, sex, race, baseline score, and tumor response status.
Treatment tolerability was measured using FACT-Lym item GP5
(“I am bothered by side effects of treatment”). Results: Patients
with an HRQOL baseline score and a postbaseline score (n=130)
were included in the analysis (median age, 66 years; 59% male;
and 88% White). With a median of 4 cycles of treatment (range,
1–26), 41% of patients experienced skin toxicity during treatment,
>80% due to non-photosensitivity cutaneous reactions. Among all
9 evaluated scores (EQ-5D visual analog scale, FACT-Lym subscale,
and composite scores) for visits up to cycle 9 (n20), there were no
signifi cant differences (P>0.05) between patients with and without
skin toxicity except for the FACT-Lym total at cycle 9 (worse in
patients with skin toxicity). A majority of patients (60%) were “not
at all” or “a little bit” bothered in both groups at each cycle, although
a higher percentage of patients with skin toxicity reported “a little
bit” than those without skin toxicity after 2 cycles. Conclusions:
Patients with skin toxicity while receiving Lonca did not experience different HRQOL compared with patients without skin toxicity
in most visits. Lonca was tolerated well even among patients with
skin toxicity. (Sponsored by ADC Therapeutics)..
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Spira A, Zhou X, Liao L, Yu E, Chen L, Lau A, et al. ABCL-316 Health-Related Quality of Life and Tolerability in Patients With/Without Skin Toxicity During Loncastuximab Tesirine Treatment in a Phase 2 Clinical Trial (LOTIS-2). Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S371-S2. PubMed PMID: 36164076. Epub 2022/09/28. eng.